BG MEDICINE INC's gross profit margin for the second quarter of its fiscal year 2015 is essentially unchanged when compared to the same period a year ago. Even though sales decreased, the net income has increased. BG MEDICINE INC has very weak liquidity. Currently, the Quick Ratio is 0.12 which clearly shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 159.64% from the same quarter last year. The key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY15||Q2 FY14|
|Net Sales ($mil)||0.51||0.8|
|Net Income ($mil)||-2.03||-2.17|
|Balance Sheet||Q2 FY15||Q2 FY14|
|Cash & Equiv. ($mil)||0.18||9.54|
|Total Assets ($mil)||1.37||11.24|
|Total Debt ($mil)||1.67||5.15|
|Profitability||Q2 FY15||Q2 FY14|
|Gross Profit Margin||66.14||64.83|
|Return on Assets||-519.32||-88.5|
|Return on Equity||0.0||-249.82|
|Debt||Q2 FY15||Q2 FY14|
|Share Data||Q2 FY15||Q2 FY14|
|Shares outstanding (mil)||8.66||8.6|
|Div / share||0.0||0.0|
|Book value / share||-0.27||0.46|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||240614.0||240281.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. Along with this, the price-to-book ratio is also meaningless due to a negative book value for the company, making any comparisons useless. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.
|BGMD NM||Peers 42.52||BGMD NM||Peers 26.75|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
BGMD's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
BGMD's P/CF is negative making the measure meaningless.
|BGMD NA||Peers 27.05||BGMD NA||Peers 1.16|
Neutral. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth potential.
Ratio not available.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|BGMD NM||Peers 5.91||BGMD 36.37||Peers 33.46|
Neutral. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
BGMD's P/B is negative making this valuation measure meaningless.
Average. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
BGMD is expected to keep pace with its peers on the basis of earnings growth.
|BGMD 2.53||Peers 36.21||BGMD -41.06||Peers 12.75|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
BGMD is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
BGMD significantly trails its peers on the basis of sales growth
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas